Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Dec;20(6):573-600.
doi: 10.1016/s0197-2456(99)00031-8.

The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1

Age-Related Eye Disease Study Research Group
Clinical Trial

The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1

Age-Related Eye Disease Study Research Group. Control Clin Trials. 1999 Dec.

Abstract

The Age-Related Eye Disease Study (AREDS) was initially conceived as a long-term multicenter, prospective study of the clinical course of age-related macular degeneration (AMD) and age-related cataract. Data on progression rates and risk factors from the study will increase understanding of the clinical course of both conditions, generate hypotheses about etiology, and aid in the design of clinical trials of potential interventions. In addition to collecting natural history data, AREDS includes a clinical trial of high-dose vitamin and mineral supplements for AMD and a clinical trial of high-dose vitamin supplements for cataract. The clinical trials were initiated largely because of the widespread public use in the United States of commercially available pharmacologic doses of vitamins and minerals to treat these two eye conditions and the absence of definitive studies on the safety and efficacy of their use. Important design issues for the clinical trials include: defining cataract and AMD, estimating event rates, determining the type and dosage of vitamins and minerals to be tested for each condition, and identifying the parameters necessary for monitoring safety and efficacy. This paper describes the AREDS design, including the study rationale and operational structure, and the approach adopted to combine, for two diseases, clinical trials with a natural history study.

PubMed Disclaimer

Figures

Figure 1
Figure 1
AREDS Randomization schema.
Figure 2
Figure 2
AREDS organization.
Figure 3
Figure 3
Overview of study visits.
See this image and copyright information in PMC

References

    1. Sorsby A. Reports on Public Health and Medical Subjects. No 114. London: Her Majesty’s Stationary Office, 1966.
    1. Kahn HA, Moorhead HB. Statistics on Blindness in the Model Reporting Area. 1969–1970 Washington, D.C.: USDHEW, PHS Publication No. (NIH); 1973:73–427.
    1. National Advisory Eye Council. Report of the Retinal and Choroidal Diseases Panel. Vision Research-A National Plan: 1983–1987 Bethesda, MD: U.S. Department of Health and Human Services; 1984.
    1. National Advisory Eye Council. Report of the Cataract Panel. Vision Research—A National Plan: 1983–1987 Bethesda, MD: U.S. Department of Health and Human Services; 1984.
    1. Thylefors B, Négrel AD, Pararajasegaram R, Dadzie KY. Global data on blindness. Bull WHO. 1995;73(1):115–121. - PMC - PubMed

Publication types

MeSH terms